The novel coronavirus Disease-2019 (COVID-19) : (Record no. 1780)

MARC details
000 -LEADER
fixed length control field 02423nam a22002537a 4500
003 - CONTROL NUMBER IDENTIFIER
control field DOH
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20201120134444.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 201120b ||||| |||| 00| 0 eng d
245 #4 - TITLE STATEMENT
Title The novel coronavirus Disease-2019 (COVID-19) :
Remainder of title mechanism of action, detection and recent therapeutic strategies /
Statement of responsibility, etc. Elahe Seyed Hosseini [and five others]
520 3# - SUMMARY, ETC.
Summary, etc. Novel coronavirus SARS-CoV-2, designated as COVID-19 by the World Health Organization (WHO) on the February 11, 2020, is one of the highly pathogenic β‐coronaviruses which infects human. Early diagnosis of COVID-19 is the most critical step to treat infection. The diagnostic tools are generally molecular methods, serology and viral culture. Recently CRISPR-based method has been investigated to diagnose and treat coronavirus infection. The emergence of 2019-nCoV during the influenza season, has led to the extensive use of antibiotics and neuraminidase enzyme inhibitors, taken orally and intravenously.<br/><br/>Currently, antiviral inhibitors of SARS and MERS spike proteins, neuraminidase inhibitors, anti-inflammatory drugs and EK1 peptide are the available therapeutic options for SARS-CoV-2 infected individuals. In addition, Chloroquine, which was previously used for malarial and autoimmune disease, has shown efficacy in the 2019-nCoV infection treatment. In severe hypoxaemia, a combination of antibiotics, α-interferon, lopinavir and mechanical ventilation can effectively mitigate the symptoms. Comprehensive knowledge on the innate and adaptive immune responses, will make it possible to propose potent antiviral drugs with their effective therapeutic measures for the prevention of viral infection. This therapeutic strategy will help patients worldwide to protect themselves against severe and fatal viral infections, that potentially can evolve and develop drug resistance, and to reduce mortality rates.
580 ## - LINKING ENTRY COMPLEXITY NOTE
Linking entry complexity note In: Virology, 2020 vol. 551, pages: 1-9<br/><br/>
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Coronavirus
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Severe Acute Respiratory Syndrome
General subdivision therapy
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term Immune response
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Hosseini, Elahe Seyed
Titles and other words associated with a name PhD
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Kashani, Narjes Riahi
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Nikzad, Hossein
Titles and other words associated with a name PhD
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Azadbakht, Javid
Titles and other words associated with a name PhD
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Bafrani, Hassan Hassani
Titles and other words associated with a name PhD
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Kashani, Hamed Haddad
Titles and other words associated with a name PhD
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://www.sciencedirect.com/science/article/pii/S0042682220301720">https://www.sciencedirect.com/science/article/pii/S0042682220301720</a>
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type COVID 19 Resource
999 ## -
-- 1780
-- 1780
Holdings
Withdrawn status Lost status Damaged status Not for loan Home library Current library Shelving location Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
        DOH Central Library DOH Central Library Electronic Resource Section 11/20/2020   COVID-19-000046 D0001C000046 11/20/2020 11/20/2020 COVID 19 Resource